Meta-analysis of the association of dermatomyositis and polymyositis with cancer

British Journal of Dermatology

Volumn 169, Issue 4, 2013, Pages 838-847

  Wang, J ^a   Guo, G ^a   Chen, G ^b   Wu, B ^c   Lu, L ^c   Bao, L ^d  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTHRITIS; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DYSPHAGIA; HUMAN; INTERSTITIAL LUNG DISEASE; NEOPLASM; POLYMYOSITIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEX; SKIN NECROSIS;

AGE FACTORS; CASE-CONTROL STUDIES; DEGLUTITION DISORDERS; DERMATOMYOSITIS; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NECROSIS; NEOPLASMS; POLYMYOSITIS; PUBLICATION BIAS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SKIN;

EID: 84885605759     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12564     Document Type: Article

References (44)

1. Sigurgeirsson B, Lindelöf B, Edhag O, Allander E,. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326: 363-7.
2. Buchbinder R, Forbes A, Hall S, et al,. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134: 1087-95.
3. Zampieri S, Valente M, Adami N, et al,. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev 2010; 9: 449-53.
4. Hill CL, Zhang Y, Sigurgeirsson B, et al,. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100.
5. András C, Ponyi A, Constantin T, et al,. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008; 35: 438-44.
6. Naschitz JE, Rosner I, Rozenbaum M, et al,. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum 1999; 29: 43-55.
7. Bonnetblanc JM, Bernard P, Fayol J,. Dermatomyositis and malignancy. A multicenter cooperative study. Dermatologica 1990; 180: 212-16.
8. Airio A, Pukkala E, Isomaki H,. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995; 22: 1300-3.
9. Sparsa A, Liozon E, Herrmann F, et al,. Routine versus extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 2002; 138: 885-90.
10. Basset-Seguin N, Roujeau JC, Gherardi R, et al,. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol 1990; 126: 633-7.
11. Nishikai M, Sato A,. Low incidence of antinuclear antibodies in dermatomyositis with malignancy. Ann Rheum Dis 1990; 49: 422.
12. Duncan AG, Richardson JB, Klein JB, et al,. Clinical, serologic, and immunogenetic studies in patients with dermatomyositis. Acta Derm Venereol 1991; 71: 312-16.
13. Gallais V, Crickx B, Belaich S,. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. Ann Dermatol Venereol 1996; 123: 722-6.
14. Whitmore SE, Anhalt GJ, Provost TT, et al,. Serum CA-125 screening for ovarian cancer in patients with dermatomyositis. Gynecol Oncol 1997; 65: 241-4.
15. Hidano A, Torikai S, Uemura T, Shimizu S,. Malignancy and interstitial pneumonitis as fatal complications in dermatomyositis. J Dermatol 1992; 19: 153-60.
16. Bohan A, Peter JB,. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
17. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
18. Wells GA, Shea B, O'Connell D, et al,. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp (last accessed 6 August 2013).
19. Antiochos BB, Brown LA, Li Z, et al,. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, U.S.A. J Rheumatol 2009; 36: 2704-10.
20. So MW, Koo BS, Kim YG, et al,. Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol 2011; 38: 2432-5.
21. Ponyi A, Constantin T, Garami M, et al,. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 2005; 1051: 64-71.
22. Prohic A, Kasumagic-Halilovic E, Simic D, Selmanagic A,. Clinical and biological factors predictive of malignancy in dermatomyositis. J Eur Acad Dermatol Venereol 2009; 23: 591-2.
23. Fardet L, Dupuy A, Gain M, et al,. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009; 88: 91-7.
24. Azuma K, Yamada H, Ohkubo M, et al,. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 2011; 21: 178-83.
25. Amerio P, Girardelli CR, Proietto G, et al,. Usefulness of erythrocyte sedimentation rate as tumor marker in cancer associated dermatomyositis. Eur J Dermatol 2002; 12: 165-9.
26. Wu XN,. Clinical analysis of 147 patients with dermatomyositis. Master's degree thesis, Sun Yat-Sen University, 2010.
27. Lian L, Xu JH,. Clinical analysis of 20 patients with polymyositis/dermatomyositis associated with malignancy. J Clin Intern Med 2005; 22: 16-17.
28. Zou Y, Yang YX, Chen XP,. Clinical analysis of 22 patients with dermatomyositis and polymyositis complicating malignancy. J Pract Dermatol 2009; 2: 9-13.
29. Tang FL, Zhao JS, Zhang XH,. Malignancy in patients with dermatomyositis/polymyositis. Chin J Rheumatol 2000; 4: 75-7.
30. Yu XH, Liu XM,. Clinical analysis of malignancy and death in dermatomyositis. Chin J Derm Venereol 2004; 18: 544-5.
31. Zhou YN, Chen AM, Zhou NH,. Clinical analysis of patients with dermatomyositis complicated with malignancies. J Clin Dermatol 2012; 41: 133-5.
32. Chen Y, Wang GC,. Retrospective study of idiopathic inflammatory myopathies associated with malignancy. Chin J Clin 2008; 2: 645-51.
33. Rose C, Hatron PY, Brouillard M, et al,. Predictive signs of cancers in dermatomyositis. Study of 29 cases. Rev Med Interne 1994; 15: 19-24.
34. Burnouf M, Mahé E, Verpillat P, et al,. Cutaneous necrosis is predictive of cancer in adult dermatomyositis. Ann Dermatol Venereol 2003; 130: 313-16.
35. Hunger RE, Durr C, Brand CU,. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology 2001; 202: 123-6.
36. Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O'Callaghan A, et al,. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64: 523-32.
37. Targoff IN, Mamyrova G, Trieu EP, et al,. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682-9.
38. Yoshifuji H, Fujii T, Kobayashi S, et al,. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 233-41.
39. Barral PM, Sarkar D, Su ZZ, et al,. Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity. Pharmacol Ther 2009; 124: 219-34.
40. Nakashima R, Imura Y, Kobayashi S, et al,. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 2010; 49: 433-40.
41. Sato S, Hirakata M, Kuwana M, et al,. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571-6.
42. Sato S, Hoshino K, Satoh T, et al,. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60: 2193-200.
43. Fiorentino D, Chung L, Zwerner J, et al,. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 25-34.
44. Gherardi RK,. Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis. Presse Med 2011; 40: e209-18.